In preparation for the commercialization of its two late-stage products, the biopharmaceutical firm plans to form NewCo to focus on developing and commercializing its treatment for cutaneous T-cell lymphoma.

Drayton Wise joined Insmed Inc. in 2014 and most recently served as senior vice president, head of U.S., and general manager of Arikayce, the company's FDA-approved lung disease drug.

The moves expand the Flanders supplier's reach further across the Garden State as well as into eastern and central Pennsylvania and upstate New York and Connecticut.

Dr. Peter Shin, who has served as section chief of hospital medicine since 2015, succeeds Dr. Alexandra Gottdiener, who was named to the role in 2009.

Dr. Suja Mathew will focus on three key areas: optimizing patient access to the system's full network of care, elevating research and academic programs, and continuing AHS's commitment to high-quality care.

The funding will go toward 28 projects to modernize systems for nearly 6 million state residents.

"Having a vaccine platform such as this available has the potential to accelerate worldwide vaccination campaigns addressing future health emergencies, including other global pandemics as seen with COVID-19,” said research collaborator Axel Lehrer, an associate professor at the University of Hawaiʽi at Mānoa.

The president and CEO of the Health Care Institute of New Jersey talks about where growth in the life sciences industry will come from in the near future, government moves to reign in health care costs and the business climate in the state.

RECOVER is a $470 million National Institutes of Health initiative to understand the frequency and development of the condition, in which people have prolonged symptoms or develop new or returning symptoms after the initial phase of infection. The university's work, called CLOCK, looks at the effect on kids.

The panel will discuss how – and why – the crisis is affecting certain populations. It is presented by the Partnership for a Drug-Free New Jersey and the Office of the New Jersey Coordinator of Addiction Responses and Enforcement Strategies.

According to the Roseland-based company, the computer-controlled injection was designed to reduce the number of unintentional dural punctures.

Because it will have access to the clinical studies and facilities of its parent company — one of the largest pharmaceutical firms in China — Luzsana Biotechnology will be able to lower development costs in the hopes of offering affordable drugs to more people globally.